Skip to main content

Table 3 Summary of planned dosimetric parameters and day-to-day dosimetric results

From: Per-fraction positional and dosimetric performance of prone breast tangential radiotherapy on Halcyon™ linear accelerator assessed with daily rapid kilo-voltage cone beam computed tomography: a single-institution pilot study

Variable Value, median (range) Wilcoxon P value
Planned dosimetric quantities   
 Breast PTV Eval   
  D95% [%] 97.73 (93.63–98.64)
  V90% [%] 99.50 (95.50–100.00)
  V105% [%] 0.10 (0.00–41.10)
 BODY   
  V90% [cc] 1174.64 (863.13–1698.72)
  V105% [cc] 3.67 (0.00–390.63)
  Global max dose [%] 105.59 (104.94–106.92)
Daily dosimetric quantities   
 Breast PTV Eval   
  D95% [%] 97.74 (82.56–99.51)a N.S
  V90% [%] 99.30 (94.20–100.00)a N.S
  V105% [%] 13.15 (0.00–72.50)b 1.5 × 10−4
 BODY   
  V90% [cc] 1107.75 (831.38–1905.60)
  V105% [cc] 130.45 (0.00–640.39)a,c N.S
  Global max dose [%] 108.85 (104.92–115.08)b 4.4 × 10−16
Difference from prescribed (Δ)   
 Breast PTV Eval   
  ΔD95% [%]  − 0.04 (− 11.07 to 1.78) N.S
  ΔV90% [%]  − 0.10 (− 1.70 to 0.20)* 6.1 × 10−11
  ΔV105% [%]  + 10.10 (− 15.40 to 72.50)* 6.3 × 10−16
BODY   
  ΔV90% [cc]  − 18.07 (− 155.14 to 206.87)* 3.4 × 10−3
  ΔV105% [cc]  + 92.40 (− 120.24 to 596.96)* 9.4 × 10−18
  ΔGlobal max dose [%]  + 2.43 (− 3.02 to 6.59)* 6.7 × 10−17
  1. cc, centimeter cubed (cm3); PTV Eval, planning treatment volume for evaluation; N.S., not significant
  2. *Significantly different from planned (two-tailed Wilcoxon)
  3. aMedian value meets objective (one-tailed Wilcoxon)
  4. bMedian significantly lower/higher than objective (one-tailed Wilcoxon)
  5. cBODY V105% does not have an objective, but ASTRO recommends < 200 cm3 to breast